The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday preview: Vote in Parliament, GlaxoSmithKline in focus

Tue, 29th Oct 2019 15:24

(Sharecast News) - The market spotlight on Wednesday will continue to be very much on Brexit, with investors keen to find out what Parliament voted the night before regarding the timing of the upcoming general elections.
But even if the opposition manages to clinch an earlier date than what the government was pushing for, any reaction from traders might be limited ahead of the US central bank's interest rate decision scheduled for after the close of markets.

Fed funds futures have fully priced-in a 25 basis point reduction in the target range for official short-term interest rates from 1.75-2.0% to 1.5-1.75%.

But some economists still se the Federal Reserve holding fire, meaning that there was room for some investors to be left disappointed.

In the background, US consultancy ADP is set to publish its private sector payrolls report for October at 1215 GMT, followed by a preliminary third quarter gross domestic product a quarter of an hour afterwards.

Across the Channel meanwhile, readings are due out on German unemployment in October and surveys of euro area consumer and industrial confidence for the same month.



On the corporate side of things, and for GlaxoSmithKline, analysts at Deutsche Bank were anticipating an approximately 3.0% rise in group sales for the third quarter at constant exchange rates.

Vaccine sales were seen growing by roughly 11.0% CER, helped by sales of Shingrix and early deliveries of its flu vaccines.

Sales at its consumer arm were seen up by 3.0% CER but down by 1.0% on the pharma side of the business.

Margins meanwhile were seen 270 basis points lower year-on-year following its purchase of Tesaro and due to the impact of its CHC joint venture, which combined would result in a 6.0% drop in earnings per share on a CER basis.

Wednesday 30 October

INTERIM DIVIDEND PAYMENT DATE

Essentra, Shore Capital Group Ltd., Smith & Nephew, Trans-Siberian Gold, Xpediator

QUARTERLY PAYMENT DATE

Marble Point Loan Financing Limited NPV

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Business Climate Indicator (EU) (10:00)

Consumer Confidence (EU) (10:00)

Crude Oil Inventories (US) (14:30)

Economic Sentiment Indicator (EU) (10:00)

GDP (Preliminary) (US) (12:30)

Industrial Confidence (EU) (10:00)

MBA Mortgage Applications (US) (11:00)

Services Confidence (EU) (10:00)

Unemployment Rate (GER) (08:55)

Q3

Smurfit Kappa Group

FINALS

Leaf Clean Energy Co (DI)

EGMS

ADES International Holding (DI)

AGMS

Angle, Ashoka India Equity Investment Trust, Frontier Developments, Goldplat, Hargreaves Services, Ideagen, Pantheon International , Redde, Sensyne Health

UK ECONOMIC ANNOUNCEMENTS

BRC Shop Price Index (00:01)

Nationwide House Price Index (07:00)

FINAL DIVIDEND PAYMENT DATE

Haynes Publishing Group

FINAL EX-DIVIDEND DATE

North Atlantic Smaller Companies Inv Trust
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.